AP2M1 and prostate cancer: SEMA3C can activate RTK signalling and drive prostate cancer growth62, STEAP4 may promote colorectal cancer development63, MMP10 may mediate c-Fos driven cSCC development64, RAP2B is a well described oncogenic activator65 and AP2M1 may participate in senescence escape66.